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We described experiments using the MDA-MB-361.1 cell line, which was thought to be an in vivo passaged subclone of the
MDA-MB-361 cell line. The MDA-MB-361 cell line harbors HER2 amplification and an activating PIK3CA mutation (E545K). Subse-
quent molecular profiling of the MDA-MB-361.1 cell line revealed that it is actually a derivative of the MCF7 cell line that was stably
transfected to overexpress HER2 (termed MCF7-neo/HER2). MCF7 cells also harbor the activating PIK3CA mutation (E545K).
Although the conclusions from the study are unaffected, we apologize for the discrepancy.818 Cancer Cell 20, 818, December 13, 2011 ª2011 Elsevier Inc.
